trending Market Intelligence /marketintelligence/en/news-insights/trending/ye_n6chlwryiducy0ryf_a2 content esgSubNav
In This List

AmpliPhi Biosciences closes $3M direct offering

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


AmpliPhi Biosciences closes $3M direct offering

AmpliPhi Biosciences Corp. closed its previously announced registered direct offering for gross proceeds of about $3 million.

The San Diego-based developer of therapies for antibiotic-resistant infections sold 2,743,640 common shares at $1.10 per share as part of the offering.

Net proceeds will go toward general corporate purposes, including expenses for manufacturing, clinical trials and research and development.

H.C. Wainwright & Co. was the exclusive placement agent for the offering.